
Entecavir (Baraclude, Bristol-Myers Squibb) should not be used in patients coinfected by HIV and hepatitis B virus (HBV) who are not also receiving highly active antiretroviral therapy (HAART), according to an FDA-issued warning to healthcare professionals.